antibodies against ciap1 (Cell Signaling Technology Inc)
86
Structured Review
Cell Signaling Technology Inc
antibodies against ciap1
Antibodies Against Ciap1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ciap1/pm41587214-308-6-3
Average 86 stars, based on 1 article reviews
Antibodies Against Ciap1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ciap1/pm41587214-308-6-3
Average 86 stars, based on 1 article reviews
antibodies against ciap1 - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Incubation:Article Title: ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma Article Snippet: .. Membranes were incubated overnight at 4°C with primary antibodies: PARP (ATCC CS9542S), Caspase 8 (CST 9496S), Ran (BD Biosciences 610341), BID (CST 2002S), ATF4 (CST 11815S), CHOP (CST 2895S), p-FOX03a (CST 9466S), pAKT (CST 4060S), AKT (CST 2964), pERK (CST 9106S), ERK (CST 9102S), CLPX (BD Biosciences 168338), CLPP (ab124822), DR5 (CST 3969S), Blocking Assay:Article Title: DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer Article Snippet: .. The following antibodies were used at the indicated dilutions in the blocking buffer: DAB2IP (Abcam, catalog no. ab87811, RRID:AB_2041032) 1:2500, DAB2IP (Santa Cruz Biotechnology, catalog no. sc-365921, RRID:AB_10917204) 1:1,000, α-TUBULIN (Sigma, catalog no. T5168, RRID:AB_477579) 1:10,000, VINCULIN (Cell Signaling Technology, catalog no. 4650, RRID:AB_10559207) 1:1,000, pERK (Cell Signaling Technology, catalog no. 4370, RRID:AB_2315112) 1:2,000, ERK (Cell Signaling Technology, catalog no. 9102, RRID:AB_330744) 1:3,000, pAKT (Cell Signaling Technology, catalog no. 4060, RRID:AB_2315049) 1:1,000, AKT (Cell Signaling Technology, catalog no. 9272, RRID:AB_329827) 1:2,000, GAPDH (Cell Signaling Technology, catalog no. 2118, RRID:AB_561053) 1:5,000, H-RAS (Santa Cruz Biotechnology, catalog no. sc-520, RRID:AB_631670) 1:500, K-RAS (Santa Cruz Biotechnology, catalog no. sc-30, RRID:AB_627865) 1:200, N-RAS (Santa Cruz Biotechnology, catalog no. sc-519, RRID:AB_632073) 1:200, IκBα (Santa Cruz Biotechnology, catalog no. sc-371, RRID:AB_2235952) 1:1,000, p-P65 (Cell Signaling Technology, catalog no. 3033, RRID:AB_331284) 1:1,000, P65 (Abcam, catalog no. ab7970, RRID:AB_306184) 1:2,000, MCL1 (Cell Signaling Technology, catalog no. 39224, RRID:AB_2799149) 1:1,000, BCL-XL (Cell Signaling Technology, catalog no. 2764, RRID:AB_2228008) 1:1,000, BCL2 (Cell Signaling Technology, catalog no. 4223, RRID:AB_1903909) 1:1,000, TRAF1 (Cell Signaling Technology, catalog no. 4715, RRID:AB_2303912) 1:1,000, TRAF2 (Cell Signaling Technology, catalog no. 4724, RRID:AB_2209845) 1:1,000, Western Blot:Article Title: Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma Article Snippet: Cells were counted using a Countess (ThermoFisher Scientific, UK) and the mean count ± the standard error of the mean (SEM) from 3 independent experiments was calculated. .. Western blot analysis was carried out as previously described using antibodies targeting phospho-(S473)-Akt (Cell Signaling Technology Cat# 4060, RRID:AB_2315049), phospho-(T308)-Akt (Cell Signaling Technology Cat# 4056, RRID:AB_331163), pan- Akt (Cell Signaling Technology Cat# 2920, RRID:AB_1147620), PTEN (Cell Signaling Technology Cat# 9559, RRID:AB_390810), PARP (Cell Signaling Technology Cat# 9532, RRID:AB_659884), phospho-γ-H2AX (Cell Signaling Technology Cat# 9718, RRID:AB_2118009), Ubiquitin Proteomics:Article Title: CARD14 signalosome formation is associated with its endosomal relocation and mTORC1-induced keratinocyte proliferation Article Snippet: .. The following antibodies were used: anti-FLAG (M2) (Sigma, #F1804, or #F3165); anti-tubulin (TAT-1); p-IKK1/2 (2078S); p-p105 (CST, #4806); RelA (CST, #8242); p-ERK1/2 (CST, #9101); p-p38 (CST, #4511); HOIP (Merck, #SAB2102031); HOIL-1/RBCK1 (Atlas Antibodies, #HPA024185); SHARPIN (Proteintech, #14626); TRAF2 (Abcam, #ab126758); TRAF6 (Abcam, #ab40675); BCL10 (SCBT, #sc-5273); MALT1 (SCBT, #sc-28246; CST, #2494); ABIN1 (Ubiquigent, #68-0002-100); A20 (CST, #5630S); DIABLO (CST, #D5S3R); Article Title: CARD14 SIGNALOSOME FORMATION IS ASSOCIATED WITH ITS ENDOSOMAL RELOCATION AND mTORC1-INDUCED KERATINOCYTE PROLIFERATION Article Snippet: 2 Rare mutations in CARD14 promote psoriasis by inducing CARD14-BCL10-MALT1 complexes that activate NF-B and MAP kinases.. Here, the downstream signalling mechanism of the highly penetrant CARD14E138A alteration is described.. In addition to BCL10 and MALT1, CARD14E138A associated with several proteins important in innate immune signalling. |